Skip to main content
OpenTrials
Completed

NCT Number: NCT05310773

Couples Health CoOp Plus

This study addresses HIV prevention and treatment for young couples living in Cape Town, South Africa, through a comprehensive biobehavioral multilevel approach-the Couples Health CoOp Plus (CHC+).

Through a cluster randomized trial with a modified factorial design, 24 Cape Town communities consisting of catchment areas for clinics that provide antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), received either a stigma awareness and education workshop or no workshop with repeated measures. Within clinic catchment areas, 481 couples (young women and their primary male sex partners both aged 18 to 30) were recruited. These couples received HIV testing services (HTS) and/or the Couples Health CoOp Plus (CHC+), depending on their intervention arm.

The overarching aim of these interventions is to prevent new cases of HIV. It is hypothesized that communities that are assigned to the stigma awareness and education workshop will demonstrate higher levels of social acceptance and fewer cases of enacted/experienced stigma at the community level. Additionally, it is expected couples assigned to the Couples Health CoOp Plus (CHC+) intervention will have greater antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) initiation and adherence, lower alcohol and other drug (AOD) use, less sexual risk, less violence, and more positive relationship norms and communication.

Specifically, the study aims to:

Aim 1: Modify the Couples Health CoOp (CHC) intervention to include antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) in a formative phase and with review from the Community Collaborative Board (CCB) and Peer Advisory Board (PAB).

Aim 2: Evaluate the impact of a stigma awareness and education workshop on community members' attitudes and behaviors toward young women and men who use AODs and other people seeking HIV services (testing/ART/PrEP) and other health services at 4- and 8-month follow-up.

Aim 3: Test the efficacy of the Couples Health CoOp Plus (CHC+) to increase both partners' antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) initiation and adherence (primary outcome) and reduce alcohol and other drug (AOD) use, sexual risk and violence, and enhance positive relationship norms and communication relative to HIV testing services (HTS) (secondary outcomes).

Aim 4: Examine through mixed methods the interaction of a stigma awareness and education workshop and the Couples Health CoOp Plus (CHC+) on increased antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) and initiation, retention, and adherence among young women and their primary partners.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Acquired Immunodeficiency Syndrome Behavior Blood-Borne Infections Chemically-Induced Disorders Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Mental Disorders RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Social Behavior Social Stigma Stigma, Social Substance Use Substance-Related Disorders Urogenital Diseases Virus Diseases

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

South African Medical Research Council

Cape Town, Western Cape, 7500, South Africa

About this study

The Couples Health CoOp Plus (CHC+) was adapted from the Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, violence, and HIV risk. It is grounded in Social Cognitive Theory and promoted prevention strategies that addressed the relational context of equality in which sexual risk takes place. The Couples Health CoOp (CHC) has demonstrated efficacy in increasing condom use, improving relationship norms, decreasing heavy alcohol use among men, and decreasing HIV incidence among women. Long-term benefits of the Couples Health CoOp (CHC) have been explored including women reporting less fighting with their partner and men reporting being more faithful and loving. As part of this current study (Aim 1), the behavioral Couples Health CoOp (CHC) was adapted to include biomedical HIV strategies antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) and updated materials. Formative qualitative work with a Community Collaborative Board (CCB) and a Peer Advisory Board (PAB) guided the adaptation and updating of the Couples Health CoOp Plus (CHC+) intervention. The Couples Health CoOp Plus (CHC+) is a 2-module workshop delivered over two days and contains didactic and experiential lessons on alcohol and other drug (AOD) use, a status-neutral approach to the prevention and management of HIV, sexual and reproductive health (SRH), relationship norms, violence, and tools to improve communication.

Formative findings regarding clinic-level stigma and discrimination showed that stigma reduction training provided in communities surrounding healthcare clinics may reduce stigmatizing behaviors and attitudes that are enacted by family, friends, and other community members toward those seeking healthcare. The stigma reduction survey and workshop were developed and adapted as part of Aim 1 formative activities.

The study enrolled approximately 20 couples in each of the 24 communities in and around Cape Town, South Africa. Communities surrounding healthcare clinics were paired according to community demographic and socioeconomic factors and randomized to one of four arms:

  • stigma awareness and education workshop (community) and HIV testing services (HTS)/antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) (couple);
  • stigma awareness and education workshop (community), and HIV testing services (HTS)/antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) with Couples Health CoOp Plus (CHC+) (couple);
  • no stigma awareness and education workshop (community) and HIV testing services (HTS)/antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) (couple);
  • no stigma awareness and education workshop (community), and HIV testing services (HTS)/antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) with Couples Health CoOp Plus (CHC+) (couple).

As noted, couples in communities that were not assigned to receive the CHC+ intervention received HIV testing services (HTS), including provision of antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) as part of standard of care.

HIV, alcohol and other drug (AOD), and pregnancy testing was conducted at baseline and at 3- and 6-month follow-up.

Assessment of community stigma occurred at baseline with all 24 communities and the stigma awareness and education workshop occurred in only those randomized to it. The follow-up occurred within all communities at 4- and 8-months post-baseline.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Selected Inclusion Criteria (for Couples):

  • 18 to 30 years old
  • Is in a relationship with a primary partner
  • Had recent condomless sex with their primary partner
  • Has not taken PrEP or ART in the past 90 days
  • Has drunk alcohol and/or used drugs at least once a week over the past 90 days

Selected Exclusion Criteria (for Couples):

  • Not currently pregnant (for women)
  • Not currently being treated for drug-resistant tuberculosis (TB)

Treatment and study plan

Community Stigma Awareness and Education Workshop

Behavioral

Key aspects of the workshop included community stigma awareness of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. The workshop adapted a stigma-reduction curriculum based on a stigma-reduction toolkit and community HIV prevention project with community peers with skits to address stigmatizing attitudes and behaviors toward young women and men who use AODs and who may need health services, including HIV treatment and prevention. Selected modules were modified from the existing clinic-based training to fit community stigma awareness and attitudes to focus on aspects of stigma specific to young women and men who engage in syndemic-related behaviors who live in their communities. The stigma awareness and education workshop was delivered in communities randomized to receive workshops (N=12 communities).

Couples Health CoOp Plus (CHC+)

Behavioral

The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, violence, and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporated antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; N=240 couples).

Primary outcomes

  1. Antiretroviral Therapy (ART) Initiation [individual and couple-level]

    Time frame: 3-month follow-up

    ART initiation will be measured using initiation information recorded in the participant's clinic medical record.

  2. Antiretroviral Therapy (ART) Initiation [individual and couple-level]

    Time frame: 6-month follow-up

    ART initiation will be measured using initiation information recorded in the participant's clinic medical record.

  3. Pre-Exposure Prophylaxis (PrEP) Initiation [individual and couple-level]

    Time frame: 3-month follow-up

    Pre-exposure prophylaxis (PrEP) initiation will be measured using initiation information recorded in the participant's clinic medical record.

  4. Pre-Exposure Prophylaxis (PrEP) Initiation [individual and couple-level]

    Time frame: 6-month follow-up

    Pre-exposure prophylaxis (PrEP) initiation will be measured using initiation information recorded in the participant's clinic medical record.

  5. Biological: Antiretroviral Therapy (ART) Adherence [individual and couple-level]

    Time frame: 3-month follow-up

    ART adherence will be measured using viral load or cluster of differentiation 4 (CD4) count measures recorded in the participant's medical record. Threshold for adherence will be cluster of differentiation 4 (CD4) count (more than 200) and HIV viral load (less than 50 copies per ml).

  6. Biological: Antiretroviral Therapy (ART) Adherence [individual and couple-level]

    Time frame: 6-month follow-up

    ART adherence will be measured using viral load or cluster of differentiation 4 (CD4) count measures recorded in the participant's medical record. Threshold for adherence will be cluster of differentiation 4 (CD4) count (more than 200) and HIV viral load (less than 50 copies per ml).

  7. Self-Report: Antiretroviral Therapy (ART) Adherence [individual and couple-level]

    Time frame: 3-month follow-up

    Self-report past 30-day use, missed doses and patterns of use of antiretroviral therapy (ART) for self-report adherence will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  8. Self-Report: Antiretroviral Therapy (ART) Adherence [individual and couple-level]

    Time frame: 6-month follow-up

    Self-report past 30-day use, missed doses and patterns of use of antiretroviral therapy (ART) for self-report adherence will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  9. Biological: Pre-Exposure Prophylaxis (PrEP) Adherence [individual and couple-level]

    Time frame: 3-month follow-up

    Tenofovir Diphosphate (TFV-DP) and FTC Triphosphate (FTC-TP) concentrations in dried blood spots (DBS) with drug concentrations of greater than 700 femtomoles (fmol)/liters(L) will be considered adherent to pre-exposure prophylaxis (PrEP).

  10. Biological: Pre-Exposure Prophylaxis (PrEP) Adherence [individual and couple-level]

    Time frame: 6-month follow-up

    Tenofovir Diphosphate (TFV-DP) and FTC Triphosphate (FTC-TP) concentrations in dried blood spots (DBS) with drug concentrations of greater than 700 femtomoles (fmol)/liters(L) will be considered adherent to pre-exposure prophylaxis (PrEP).

  11. Self-Report: Pre-Exposure Prophylaxis (PrEP) Adherence [individual and couple-level]

    Time frame: 3-month follow-up

    Self-report past 30-day use, missed doses and patterns of use of pre-exposure prophylaxis (PrEP) for self-report adherence will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  12. Self-Report: Pre-Exposure Prophylaxis (PrEP) Adherence [individual and couple-level]

    Time frame: 6-month follow-up

    Self-report past 30-day use, missed doses and patterns of use of pre-exposure prophylaxis (PrEP) for self-report adherence will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  13. Antiretroviral Therapy (ART) Persistence and Discontinuation [individual and couple-level]

    Time frame: 3-month follow-up

    Number of antiretroviral therapy (ART) refills since initiation recorded in clinic medical records.

  14. Antiretroviral Therapy (ART) Persistence and Discontinuation [individual and couple-level]

    Time frame: 6-month follow-up

    Number of antiretroviral therapy (ART) refills since initiation recorded in clinic medical records.

  15. Self-Report: Antiretroviral therapy (ART) Persistence and Discontinuation [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported time in months on antiretroviral therapy (ART) since initiation will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  16. Self-Report: Antiretroviral therapy (ART) Persistence and Discontinuation [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported time in months on antiretroviral therapy (ART) since initiation will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  17. Data Extraction: Pre-Exposure Prophylaxis (PrEP) Persistence and Discontinuation [individual and couple-level

    Time frame: 3-month follow-up

    Number of pre-exposure prophylaxis (PrEP) refills since initiation as recorded clinic medical records.

  18. Data Extraction: Pre-Exposure Prophylaxis (PrEP) Persistence and Discontinuation [individual and couple-level

    Time frame: 6-month follow-up

    Number of pre-exposure prophylaxis (PrEP) refills since initiation as recorded clinic medical records.

  19. Self-Report: Pre-Exposure Prophylaxis (PrEP) Persistence and Discontinuation [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported time in months on pre-exposure prophylaxis (PrEP) since initiation on pre-exposure prophylaxis (PrEP) will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  20. Self-Report: Pre-Exposure Prophylaxis (PrEP) Persistence and Discontinuation [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported time in months on pre-exposure prophylaxis (PrEP) since initiation on pre-exposure prophylaxis (PrEP) will be measured using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  21. Data Extraction: Antiretroviral therapy (ART) Retention

    Time frame: 3-month follow-up

    Antiretroviral therapy (ART) retention in care will be measured as attendance to follow-up visits as recorded in clinic medical records.

  22. Data Extraction: Antiretroviral therapy (ART) Retention

    Time frame: 6-month follow-up

    Antiretroviral therapy (ART) retention in care will be measured as attendance to follow-up visits as recorded in clinic medical records.

  23. Self-Report: Pre-exposure Prophylaxis (PrEP) Retention [individual and couple-level]

    Time frame: 3-month follow-up

    Self-report pre-exposure prophylaxis (PrEP) retention in care will be measured as attendance to follow-up visits using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  24. Self-Report: Pre-exposure Prophylaxis (PrEP) Retention [individual and couple-level]

    Time frame: 6-month follow-up

    Self-report pre-exposure prophylaxis (PrEP) retention in care will be measured as attendance to follow-up visits using the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

Secondary outcomes

  1. Community Stigma [structural level]

    Time frame: Baseline

    Surveys will be used to measure stigmatizing attitudes and perceptions towards people who use alcohol and other drugs (AODs), living with HIV and seeking and antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) services for prevention. Greater values indicate higher levels of community-level stigma and discrimination.

  2. Community Stigma [structural level]

    Time frame: 4-month follow-up

    Surveys will be used to measure stigmatizing attitudes and perceptions towards people who use alcohol and other drugs (AODs), living with HIV and seeking and antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) services for prevention. Greater values indicate higher levels of community-level stigma and discrimination.

  3. Community Stigma [structural level]

    Time frame: 8-month follow-up

    Surveys will be used to measure stigmatizing attitudes and perceptions towards people who use alcohol and other drugs (AODs), living with HIV and seeking and antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) services for prevention. Greater values indicate higher levels of community-level stigma and discrimination.

  4. Biological: Drug use [individual level]

    Time frame: Baseline

    Recent drug use (amphetamine, cocaine, methamphetamine, marijuana [THC], opiates and/or Mandrax) will be measured using a rapid urine-based drug screening test panel.

  5. Biological: Drug use [individual level]

    Time frame: 3-month follow-up

    Recent drug use (amphetamine, cocaine, methamphetamine, marijuana [THC], opiates and/or Mandrax) will be measured using a rapid urine-based drug screening test panel.

  6. Biological: Drug use [individual level]

    Time frame: 6-month follow-up

    Recent drug use (amphetamine, cocaine, methamphetamine, marijuana [THC], opiates and/or Mandrax) will be measured using a rapid urine-based drug screening test panel.

  7. Biological: Alcohol use [individual level]

    Time frame: Baseline

    Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.

  8. Biological: Alcohol use [individual level]

    Time frame: 3-month follow-up

    Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.

  9. Biological: Alcohol use [individual level]

    Time frame: 6-month follow-up

    Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.

  10. Self-Report: Violence [individual and couple-level]

    Time frame: Baseline

    Self-report emotional, physical, and sexual abuse, recent victimization, and family violence & experience of physical & sexual abuse will be measured using the World Health Organization (WHO) assessment of emotional, physical, & sexual abuse and the Revised Risk Behavior Assessment (RRBA).

  11. Self-Report: Violence [individual and couple-level]

    Time frame: 3-month follow-up

    Self-report emotional, physical, and sexual abuse, recent victimization, and family violence & experience of physical & sexual abuse will be measured using the World Health Organization (WHO) assessment of emotional, physical, & sexual abuse and the Revised Risk Behavior Assessment (RRBA).

  12. Self-Report: Violence [individual and couple-level]

    Time frame: 6-month follow-up

    Self-report emotional, physical, and sexual abuse, recent victimization, and family violence & experience of physical & sexual abuse will be measured using the World Health Organization (WHO) assessment of emotional, physical, & sexual abuse and the Revised Risk Behavior Assessment (RRBA).

  13. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: Baseline

    Self-reported frequency of condom use at last sex over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  14. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported frequency of condom use at last sex over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  15. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported frequency of condom use at last sex over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  16. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: Baseline

    Self-reported frequency of alcohol and other drug (AOD) use prior to sex in the last 3 months as measured by the Pretoria Risk Behavior Assessment (PRBA+).

  17. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported frequency of alcohol and other drug (AOD) use prior to sex in the last 3 months as measured by the Pretoria Risk Behavior Assessment (PRBA+).

  18. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported frequency of alcohol and other drug (AOD) use prior to sex in the last 3 months as measured by the Pretoria Risk Behavior Assessment (PRBA+).

  19. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: Baseline

    Self-reported number of sex partners, concurrent sexual partners and sex trading partners over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  20. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported number of sex partners, concurrent sexual partners and sex trading partners over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  21. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported number of sex partners, concurrent sexual partners and sex trading partners over the past 3 months measured by the Pretoria Risk Behavior Assessment (PRBA+).

  22. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: Baseline

    Self-report responses on the single item measured by the Pretoria Risk Behavior Assessment (PRBA+) will be used to assess use of contraception and types of contraception.

  23. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 3-month follow-up

    Self-report responses on the single item measured by the Pretoria Risk Behavior Assessment (PRBA+) will be used to assess use of contraception and types of contraception.

  24. Self-Report: Sexual Risk [individual and couple-level]

    Time frame: 6-month follow-up

    Self-report responses on the single item measured by the Pretoria Risk Behavior Assessment (PRBA+) will be used to assess use of contraception and types of contraception.

  25. Self-Report: Relationship Norms [individual and couple-level]

    Time frame: Baseline

    Self-reported attitudes about traditional relationship roles, empowerment, and assertiveness will be measured by a modified scale assessing beliefs about relationship norms and the Pretoria Risk Behavior Assessment (PRBA+).

  26. Self-Report: Relationship Norms [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported attitudes about traditional relationship roles, empowerment, and assertiveness will be measured by a modified scale assessing beliefs about relationship norms and the Pretoria Risk Behavior Assessment (PRBA+).

  27. Self-Report: Relationship Norms [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported attitudes about traditional relationship roles, empowerment, and assertiveness will be measured by a modified scale assessing beliefs about relationship norms and the Pretoria Risk Behavior Assessment (PRBA+).

  28. Self-Report: Communication [individual and couple-level]

    Time frame: Baseline

    Self-reported communication between partners regarding testing, HIV and sexually transmitted infection (STI) status, other partners, sexual negotiation, and condom use as measured by the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  29. Self-Report: Communication [individual and couple-level]

    Time frame: 3-month follow-up

    Self-reported communication between partners regarding testing, HIV and sexually transmitted infection (STI) status, other partners, sexual negotiation, and condom use as measured by the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  30. Self-Report: Communication [individual and couple-level]

    Time frame: 6-month follow-up

    Self-reported communication between partners regarding testing, HIV and sexually transmitted infection (STI) status, other partners, sexual negotiation, and condom use as measured by the Revised Risk Behavior Assessment (RRBA)/Pretoria Risk Behavior Assessment (PRBA+).

  31. Self-Report: Observed or Knowledge of Stigma [individual and couple-level]

    Time frame: Baseline

    Observations or knowledge of stigma perpetrated by others in the community will be measured by stigma items adapted from previous research.

  32. Self-Report: Observed or Knowledge of Stigma [individual and couple-level]

    Time frame: 3-month follow-up

    Observations or knowledge of stigma perpetrated by others in the community will be measured by stigma items adapted from previous research.

  33. Self-Report: Observed or Knowledge of Stigma [individual and couple-level]

    Time frame: 6-month follow-up

    Observations or knowledge of stigma perpetrated by others in the community will be measured by stigma items adapted from previous research.

Sponsors and collaborators

Lead sponsor

RTI International

Other

Collaborators

  • Medical Research Council, South Africa

Registry information

Official study title

Multilevel Strategies & Tailored HIV Prevention and Care for Young Couples Who Use Alcohol and Other Drugs Across Cape Town: Couples Health CoOp Plus

Acronym: CHC+

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Apr 5, 2022
Registry last updated
Nov 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.